Ribbon Bio key facts
as of Oct 2026- Developer of DNA technologies designed to meet the tailored needs of synthetic biology.
- Ribbon Bio is valued at approximately $46.6M as of Oct 2026 (last reported valuation).
- It has raised $27.3M; the latest was Later Stage VC ($5.2M) in Feb 2025.
- Notable investors include Austria Wirtschaftsservice, Lansdowne Partners, EIC Scaling Club, Hadean Ventures, Helicase Venture — 10 tracked in total.
- Status: Privately Held (backing).
Ribbon Bio's last reported valuation, Feb 2025. Nothing priced has surfaced since.
- ·Watch Ribbon Bio: the Monday email on marks, rounds and moves
Ribbon Bio funding rounds
No funding rounds for Ribbon Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ribbon Bio valuation
Ribbon Bio's last reported valuation was $46.6 million in Feb 2025. No priced round, secondary trade or fund mark has surfaced since.
Ribbon Bio investors
10 investors are on record for Ribbon Bio, including Austria Wirtschaftsservice, Lansdowne Partners, EIC Scaling Club and Hadean Ventures.
About Ribbon Bio
Developer of DNA technologies designed to meet the tailored needs of synthetic biology. The company's services offer deoxyribonucleic acid for the upcoming wave of biotechnologies whether it is required to build genomes, build high-throughput libraries, make new products based on deoxyribonucleic acid, store data, compute with deoxyribonucleic acid or build deoxyribonucleic acid-based nanotechnologies devices, enabling researchers and companies to focus on libraries of deoxyribonucleic acids of lengths base pairs without economic or time constraints.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2017
- Employees
- 54
- Website
- ribbonbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.